APA

Salama J. K., Haraf D. J., Stenson K. M., Blair E. A., Witt M. E., Williams R., Kunnavakkam R., Cohen E. E. W., Seiwert T. & Vokes E. E. (20111212). A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. : Annals of oncology : official journal of the European Society for Medical Oncology.

Chicago

Salama J K, Haraf D J, Stenson K M, Blair E A, Witt M E, Williams R, Kunnavakkam R, Cohen E E W, Seiwert T and Vokes E E. 20111212. A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. : Annals of oncology : official journal of the European Society for Medical Oncology.

Harvard

Salama J. K., Haraf D. J., Stenson K. M., Blair E. A., Witt M. E., Williams R., Kunnavakkam R., Cohen E. E. W., Seiwert T. and Vokes E. E. (20111212). A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. : Annals of oncology : official journal of the European Society for Medical Oncology.

MLA

Salama J K, Haraf D J, Stenson K M, Blair E A, Witt M E, Williams R, Kunnavakkam R, Cohen E E W, Seiwert T and Vokes E E. A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. : Annals of oncology : official journal of the European Society for Medical Oncology. 20111212.